Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504309 · ClinicalTrials.gov registry record · NA

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

A NA study of Hypertriglyceridemia, sponsored by Penn State University.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT00504309 is a NA study of Hypertriglyceridemia that has completed, run by Penn State University. The registered enrollment target is 28 participants, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504309, a NA study of Hypertriglyceridemia, has completed, sponsored by Penn State University.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.

Conditions Studied

Interventions

  • DRUG 4/day of 4g P-OM3 capsules
  • DRUG 4/day of 1g P-OM3 capsules
  • DRUG Corn Oil Placebo, 4 capsules/day for 8 weeks

Study Locations (1)

Pennsylvania

  • Penn State University General Clinical Research Center - University Park

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2007-07
Est. Completion 2009-01
Phase NA

Sponsor

Penn State University

219 total trials

What the Registry Record Tells You About NCT00504309

The ClinicalTrials.gov registry entry for NCT00504309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (84% lower). The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 3 interventions - of which 4/day of 4g P-OM3 capsules is the first listed.

NCT00504309 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00504309 about?

NCT00504309 is a clinical study titled "Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides". The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.

What is the current status of trial NCT00504309?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2007-07. Estimated completion is 2009-01.

What conditions does trial NCT00504309 study?

This clinical trial studies the following conditions: Hypertriglyceridemia.

What interventions are being tested in trial NCT00504309?

The interventions under investigation include: 4/day of 4g P-OM3 capsules (DRUG), 4/day of 1g P-OM3 capsules (DRUG), Corn Oil Placebo, 4 capsules/day for 8 weeks (DRUG).

Who is sponsoring clinical trial NCT00504309?

This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00504309 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.